153465-52-2

Upstream product

• 153465-48-6 2-(2-carboxyphenyl)-6-methyl-4-quinoline-carboxylic acid 
• 153465-51-1 methyl 2-(6-methylquinolin-2-yl)benzoate 
• 106-49-0 p-toluidine 
• 153465-50-0 2-(2-methoxycarbonylphenyl)-6-methyl-4-quinolinecarboxylic acid 
• 608-05-9 5-methyl-indole-2,3-dione 
• 577-56-0 2-acetyl-benzoic acid 

Downstream Products

• 187970-95-2 2-[6-(bromomethyl)quinolin-2-yl]benzoic acid 
• 153465-53-3 2-(6-methylquinolin-2-yl)benzamide 
• 153465-66-8 2-{6-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]quinolin-2-yl}benzoic acid 
• 153465-65-7 methyl 2-{6-[(2-ethyl-5,7-dimethyl-3H-imidazo-[4,5-b]pyridin-3-yl)methyl]quinolin-2-yl}benzoate 
• 194347-19-8 2-{6-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]quinolin-2-yl}aniline 
• 167374-83-6 2-(6-bromomethyl-quinolin-2-yl)-benzoic acid methyl ester 

Relevant academic research and scientific papers

A novel trifluoromethanesulfonamidophenyl-substituted quinoline derivative, GA 0113: Synthesis and pharmacological profiles

The trifluoromethanesulfonamidophenyl-substituted quinoline GA 0113 have been synthesized from o-nitrobenzoyl chloride via a multi-step process. GA 0113 displaced specific binding of [125I]-Sar1, Ile8-Ang II to AT1 receptors in membrane from Sf9 cells. In concious normotensive dogs, GA 0113 inhibited the Ang II-induced pressor response with ID50 of 0.032mg/kg and dose-dependently increased plasma renin activity for 48h.

Process for producing 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds

Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.

Process for producing quinolin-2-yl benzoic acid compounds

A quinolin-2-yl benzoic acid compound useful as intermediates of angiotensin II antagonists which are effective for treating hypertension can be produced by decarboxylating a 2-carboxyphenyl-4-quinolinecarboxylic acid compound in which two carboxyl groups are not substituted and a benzene ring and a quinoline ring may have substituents inert to said decarboxylation reaction.

Quinoline compounds

A quinoline compound represented by the formula (1) or a salt thereof: STR1 wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.